Literature DB >> 26768807

Long-Term Outcomes Following Transvenous Lead Extraction.

Sean Gomes1, Gregory Cranney1, Michael Bennett2, Robert Giles1.   

Abstract

BACKGROUND: Complications related to a cardiac implantable electronic device sometimes require transvenous lead extraction (TLE). We report long-term follow-up of patients undergoing TLE, particularly mortality, recurrent device infection, and need for repeat procedures. METHODS AND
RESULTS: Consecutive patients undergoing TLE at a high-volume center were assessed for characteristics, indications, and outcomes. One thousand and six leads were extracted from 510 patients. Clinical success rate was 98.2% and complete procedural success was 92.2%, with one intraprocedural death. The mean follow-up was 5.5 +/- 4.9 years (range 0.2-18 years). Cumulative mortality was 3.3% at 30 days, 7.7% at 6 months, 10.0% at 1 year, and 33.0% at 10 years. Factors associated with increased long-term mortality included cardiac device infection (CDI; 33% vs 17% for non-CDI; χ² 13.8, P = 0.0003), procedural complications (43% vs 27% for no complications; χ² 4.2, P = 0.04), age (75.0 +/- 10.9 years in patients who died vs 62.7 +/- 17.2 years; P < 0.0001), and impaired renal function (creatinine 142.5 +/- 106.4 μmol/L in patients who died vs 106.3 +/- 90.7 μmol/L; P = 0.001). The rate of CDI after TLE was 3.9% (mean 11.6 months post extraction, range 0.3-84 months) and is higher in patients with retained lead fragments (13.5% vs 3.0% with complete removal; χ² 10.7, P = 0.001).
CONCLUSION: Long-term mortality following TLE is high, particularly in those with systemic infection, procedural complications, advanced age, and renal impairment. Retained fragments are a risk factor for CDI post extraction.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  infection; internal cardioverter defibrillator; lead extraction; pacemaker

Mesh:

Year:  2016        PMID: 26768807     DOI: 10.1111/pace.12812

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  7 in total

1.  Management of Cardiac Electronic Device Infections: Challenges and Outcomes.

Authors:  Rikke Esberg Kirkfeldt; Jens Brock Johansen; Jens Cosedis Nielsen
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

Review 2.  Cardiac Implantable Electronic Device Infections-Decision-Making Process in Complex Patients: Report of 3 Cases.

Authors:  Assad Mohammedzein; Aaisha Mozumder; Scott Milton
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

3.  Prognostic Value of Preoperative Echocardiographic Findings in Patients Undergoing Transvenous Lead Extraction.

Authors:  Dorota Nowosielecka; Wojciech Jacheć; Anna Polewczyk; Łukasz Tułecki; Andrzej Kleinrok; Andrzej Kutarski
Journal:  Int J Environ Res Public Health       Date:  2021-02-14       Impact factor: 3.390

4.  Eligibility for subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease.

Authors:  Christos Zormpas; Ann Sophie Silber-Peest; Jörg Eiringhaus; Henrike A K Hillmann; Stephan Hohmann; Johanna Müller-Leisse; Mechthild Westhoff-Bleck; Christian Veltmann; David Duncker
Journal:  ESC Heart Fail       Date:  2021-02-03

5.  Eligibility for subcutaneous implantable cardioverter-defibrillator in patients with left ventricular assist device.

Authors:  Christos Zormpas; Jörg Eiringhaus; Henrike A K Hillmann; Stephan Hohmann; Johanna Müller-Leisse; Jan D Schmitto; Christian Veltmann; David Duncker
Journal:  J Interv Card Electrophysiol       Date:  2020-07-01       Impact factor: 1.900

Review 6.  The subcutaneous implantable cardioverter defibrillator--review of the recent data.

Authors:  Stacy B Westerman; Mikhael El-Chami
Journal:  J Geriatr Cardiol       Date:  2018-03       Impact factor: 3.327

Review 7.  State of the art: leadless ventricular pacing : A national expert consensus of the Austrian Society of Cardiology.

Authors:  C Steinwender; P Lercher; C Schukro; H Blessberger; G Prenner; M Andreas; J Kraus; M Ammer; M Stühlinger
Journal:  J Interv Card Electrophysiol       Date:  2019-12-20       Impact factor: 1.900

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.